Dupilumab Effective for Up To 1 Year in Teens With AD: Study

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 open-label extension trial, researchers reported.

At 1 year, 86% of 50 remaining patients with weights under 60 kg (132 lb) had achieved 75% improvement (EASI-75; Eczema Area and Severity Index), and 77% of 51 remaining patients with weights over 60 kg reached that level of clearance. Only 5 (1.7%) of 294 patients had serious treatment-emergent adverse events (TEAEs).

Dr Eric Simpson

The findings back up a perception that patients can stay on dupilumab for some time instead of having to switch from one biologic to another after a few years, study co-author Eric Simpson, MD, professor of dermatology, Oregon Health & Science University in Portland, said in an interview. He added that the drug’s long-term safety profile is “very reassuring.”

The industry-funded findings of the study were released in a poster at the 2021 meeting of the World Congress of Pediatric Dermatology.

The FDA approved dupilumab, an interleukin-4 receptor alpha antagonist, for treating AD in adults in 2017; it is now approved for treating patients ages 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topicals.

The new study tracked patients who received at least 300 mg dupilumab subcutaneously every 4 weeks. The dose could be increased if needed to improve clinical response to once every 2 weeks (200 mg if baseline weight was

At 52 weeks, 37% of 52 patients with weights under 60 kg reached an Investigator Global Assessment (IGA) of 0/1, a level that had been fairly steady since week 16 (n=146). Among 51 heavier patients, 49% reached an IGA of 0/1 at 52 weeks; this percentage grew steadily since baseline.

The mean percentage change in EASI was -87% in the lower-weight group (n=50) at 52 weeks and -80.1% in the larger-weight group (n=51). The majority of the reduction in EASI occurred in the first 4 weeks of treatment.

At 52 weeks, the mean Children’s Dermatology Life Quality Index level, which judges the effect of AD on life, was judged as “small” (low) in 71 patients. At baseline, the mean level among 189 patients was “moderate.” The levels dipped below “moderate” at week 4 and never rose above “small” after that.

“Treatment-emergent adverse events (TEAEs) reported in ≥5% of patients were nasopharyngitis (21.1%), AD (19.4%), upper respiratory tract infection (12.4%), headache (9.4%), and oropharyngeal pain (5.7%),” the investigators write in the poster. They add that 6.7% of patients experienced injection-site reactions, and 8.7% of patients experienced treatment-emergent “narrow conjunctivitis,” which includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, and atopic keratoconjunctivitis.

Simpson noted that cases of conjunctivitis fell over time. It’s not clear why this adverse effect appears, he said.

He said that the findings reflect his own experience in clinic. Many of his adolescent patients took part in early dupilumab trials, he said, and dozens have been taking the drug for more than 5 years. “They just seem to get better and better,” he said.

University of Minnesota dermatologist Sheilagh Maguiness, MD, who wasn’t involved with the study, told Medscape Medical News that dupilumab remains “the safest, most effective and evidence-based therapy we had for children with moderate to severe atopic dermatitis.”

The new study’s findings are “very reassuring,” she said, and similar to those in a 2021 report that tracked long-term use of the drug in children aged 6-11.

Like Simpson, Maguiness said many pediatric patients at her clinic have stayed on the drug for more than 5 years. They still have “sustained improvement in skin disease and in their quality of life as well,” she said.

Dr Sheilagh Maguiness

There are, however, still questions about dupilumab treatment, she conceded. “For children who have responded well, when could we consider dose reduction or discontinuation? I have done this successfully just a handful of times, but I would love to see data about what percentage of pediatric patients experience rebound disease after coming off the drug and after what duration of treatment,” she said. “Another mystery that will be very interesting to unravel is the question as to whether or not early treatment with dupilumab may attenuate other atopic diseases.”

Maguiness added that “another issue specific to pediatric use of dupilumab is the recommendation surrounding vaccinations. This is an issue that should be studied in terms of antibody response and safety surrounding vaccinations, particularly as we are eagerly awaiting a pediatric FDA approval for the COVID-19 vaccine in children.”

She also urged colleagues to push back against insurers who resist paying for dupilumab. “Whether prescribing this medication on- or off-label, insurance companies are often requiring patients to try and fail other traditional immunosuppressive medications such as methotrexate, cyclosporine, or to pursue phototherapy,” she said.

“Oftentimes, these are not practical or even safe options for children for a multitude of reasons. Don’t be shy about advocating for your patients by second- or even third-level appeals to try and gain approval for children who are in need of treatment.”

The study was funded by Sanofi Genzyme and Regeneron Pharmaceuticals. The study authors report various disclosures. Simpson reports investigator (AbbVie, Eli Lilly, Galderma, Kyowa Hakko Kirin, LEO Pharma, Merck, Pfizer, Regeneron) and consultant fee relationships (AbbVie, Boehringer Ingelheim, Dermavant, Eli Lilly, Forté, Incyte, LEO Pharma, Menlo Therapeutics, Pfizer, Pierre Fabre Dermo-Cosmetics, Regeneron, Sanofi Genzyme, Valeant). Maguiness was an investigator for one of the initial pediatric dupilumab trials.

World Congress of Pediatric Dermatology: Abstract P22. Presented
September 23, 2021.

Randy Dotinga is a freelance journalist who covers medicine and health.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
10 Flu Vaccine Side Effects That Are Totally Normal thumbnail

10 Flu Vaccine Side Effects That Are Totally Normal

We said it above, but it’s really worth emphasizing: These side effects tend to be mild and last a few days at most, according to Jan Carney, M.D., M.P.H., associate dean for public health & health policy and professor of medicine at the Larner College of Medicine at the University of Vermont. But if you’re…
Read More
Voice-control smart devices might hinder kids' social and emotional development, says expert thumbnail

Voice-control smart devices might hinder kids’ social and emotional development, says expert

Credit: Unsplash/CC0 Public Domain Voice-control smart devices, such as Alexa, Siri, and Google Home might hinder children's social and emotional development, argues an expert in the use of artificial intelligence and machine learning in health care, in a viewpoint published online in the Archives of Disease in Childhood. These devices might have long-term effects by
Read More
Baby formula recalled over concerns of Cronobacter contamination thumbnail

Baby formula recalled over concerns of Cronobacter contamination

Reckitt is recalling approximately 145,000 cans of ProSobee Simply Plant-Based Infant Formula because of a possibility of cross-contamination with Cronobacter sakazakii.  According to the company announcement posted by the Food and Drug Administration, all product distributed went through extensive testing and tested negative for the bacteria, and there have been no reported adverse consumer reactions
Read More
Aishwarya Rai appears before ED in Panama Papers case thumbnail

Aishwarya Rai appears before ED in Panama Papers case

Bollywood actor Aishwarya Rai Bachchan on Monday appeared before the Enforcement Directorate in Delhi in connection with the Panama Papers case. Aishwarya Rai Bachchan's name featured in the list of 500 Indians in the Panama Papers leak. (File photo)Bollywood actor Aishwarya Rai Bachchan on Monday appeared before the Enforcement Directorate (ED) in connection with the…
Read More
Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to  16-24 weeks at two years thumbnail

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Not intended for U.S. and UK Media Berlin, June 29, 2023 – Bayer today announced the two-year (96 weeks) topline results of the pivotal clinical trial PHOTON investigating its novel aflibercept 8 mg with extended dosing regimens of up to 24 weeks in diabetic macular edema (DME) compared to the current standard of care EyleaTM
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Subscription Form

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?